Literature DB >> 10684360

Mutational analysis of COL4A5 gene in Korean Alport syndrome.

H I Cheong1, H W Park, I S Ha, Y Choi.   

Abstract

Mutational analysis of the COL4A5 gene in X-linked Alport syndrome (AS) requires an expensive and time-consuming procedure with a detection rate of 50%, at best. There have been three multicenter collaborative studies of mutation analysis in the COL4A5 gene using systematic screening of entire coding regions of the gene. This is a similar study executed in a single center in Korea. Twenty-five unrelated Korean patients with AS in whom the diagnosis was confirmed pathologically were included in the study. By systematic screening of all 51 exons of the gene using polymerase chain reaction/single-strand conformation polymorphism analysis, ten mutations were detected in 10 unrelated patients. These included one medium-sized deletion involving exon 49-51, one single base pair deletion, one nonsense point mutation, one splice site mutation, and six missense point mutations. Of the six missense mutations, four involved a glycine residue and disrupted the Gly-X-Y repeats in the collagenous domain. The overall detection rate of mutations was 40%. Although DNA analysis in AS is currently not applicable to routine clinical diagnosis due to several practical and technical problems, it is likely to replace morphological diagnosis in the near future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684360     DOI: 10.1007/s004670050025

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  6 in total

1.  Female X-linked Alport syndrome with somatic mosaicism.

Authors:  Kana Yokota; Kandai Nozu; Shogo Minamikawa; Tomohiko Yamamura; Keita Nakanishi; Hisashi Kaneda; Riku Hamada; Yoshimi Nozu; Akemi Shono; Takeshi Ninchoji; Naoya Morisada; Shingo Ishimori; Junya Fujimura; Tomoko Horinouchi; Hiroshi Kaito; Koichi Nakanishi; Ichiro Morioka; Mariko Taniguchi-Ikeda; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2016-10-31       Impact factor: 2.801

2.  X-linked Alport syndrome caused by splicing mutations in COL4A5.

Authors:  Kandai Nozu; Igor Vorechovsky; Hiroshi Kaito; Xue Jun Fu; Koichi Nakanishi; Yuya Hashimura; Fusako Hashimoto; Koichi Kamei; Shuichi Ito; Yoshitsugu Kaku; Toshiyuki Imasawa; Katsumi Ushijima; Junya Shimizu; Yoshio Makita; Takao Konomoto; Norishige Yoshikawa; Kazumoto Iijima
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-02       Impact factor: 8.237

3.  Detection of large deletion mutations in the COL4A5 gene of female Alport syndrome patients.

Authors:  Kandai Nozu; Rafal Przybyslaw Krol; Yasufumi Ohtsuka; Koichi Nakanishi; Norishige Yoshikawa; Yoshimi Nozu; Hiroshi Kaito; Kyoko Kanda; Yuya Hashimura; Yuhei Hamasaki; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2008-06-27       Impact factor: 3.714

4.  Whole exome sequencing reveals novel COL4A3 and COL4A4 mutations and resolves diagnosis in Chinese families with kidney disease.

Authors:  Fujun Lin; Fan Bian; Jun Zou; Xiangru Wu; Jianping Shan; Wei Lu; Yao Yao; Gengru Jiang; Daniel Philip Gale
Journal:  BMC Nephrol       Date:  2014-11-07       Impact factor: 2.388

5.  Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique.

Authors:  Xuechao Zhao; Chen Chen; Yanfu Wei; Ganye Zhao; Lina Liu; Conghui Wang; Junjun Zhang; Xiangdong Kong
Journal:  Mol Genet Genomic Med       Date:  2019-04-09       Impact factor: 2.183

6.  Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay.

Authors:  Tomoko Horinouchi; Tomohiko Yamamura; Shogo Minamikawa; China Nagano; Nana Sakakibara; Koichi Nakanishi; Yuko Shima; Naoya Morisada; Shinya Ishiko; Yuya Aoto; Hiroaki Nagase; Hiroki Takeda; Rini Rossanti; Shingo Ishimori; Hiroshi Kaito; Masafumi Matsuo; Kazumoto Iijima; Kandai Nozu
Journal:  Mol Genet Genomic Med       Date:  2020-06-16       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.